ImmunityBio (NASDAQ:IBRX - Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $9.51 million for the quarter.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ImmunityBio Price Performance
IBRX traded down $0.03 on Friday, hitting $2.87. The company had a trading volume of 3,686,006 shares, compared to its average volume of 6,123,598. The company's fifty day moving average price is $3.07 and its 200 day moving average price is $3.67. ImmunityBio has a 1-year low of $2.28 and a 1-year high of $10.53. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -3.12 and a beta of 0.82.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on IBRX shares. HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of ImmunityBio in a report on Thursday. BTIG Research began coverage on ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 price target on the stock. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a research report on Thursday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $12.19.
Get Our Latest Stock Report on ImmunityBio
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
